On November 6, 2017 STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapies modulating RNA epigenetics, reported the appointment of Professor Paul Workman to its Board (Press release, STORM Therapeutics, NOV 6, 2017, View Source [SID1234561049]). This appointment continues STORM’s evolution of its management and advisory networks as it fulfils its ambition to become the leading therapeutics company in RNA epigenetic modulation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEO of STORM Therapeutics, Keith Blundy commented on the appointment: "I am pleased to welcome Paul asIndependent Director to STORM’s board. Paul brings a wealth of experience in cancer biology and drug discovery, in addition to the translational expertise of moving emerging biology to therapeutic applications through his experience of leading a world class cancer institute and being a founder of companies such as Piramed. We look forward to Paul’s input on development and positioning of STORM’s emerging RNA epigenetics platform and programmes."

Professor Paul Workman, Chief Executive and President of The Institute of Cancer Research, London, said: "I am delighted to be joining the board of STORM and working with the company in this exploding area of biology. RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies. I look forward to working with the board to help guide STORM’s innovative research programmes, adding my experience from drug discovery in academia, pharma and biotech."